Chemical Stability of Plerixafor after Opening of Single-Use Vial

Abstract

Background: The addition of the immunostimulant plerixafor to the current standard-of-care regimens of granulocyte colony-stimulating growth factor with or without chemotherapy has improved clinical results in terms of successful stem cell mobilization and the outcomes of stem cell transplant in various settings. With this medical innovation has come an added financial cost for institutions where stem cell transplants are routinely performed, and there may be a further financial burden when the contents of partial vials of the drug are wasted, given that plerixafor vials (Mozobil, Sanofi-Aventis Canada Inc) are currently deemed suitable only for single use.

Reduced‐dose plerixafor as a mobilization strategy in autologous hematopoietic cell transplantation: a proof of concept study

“…Considering a cutoff limit of 20 CD34+ cells/μL before plerixafor, most patients (75%) in our study group were poor mobilizers and they benefited from receiving plerixafor at a reduced dose. Interestingly, recent evidence has proven the chemical stability of plerixafor under refrigeration and at room temperature for up to 4 weeks, validating our strategy . The high cost of plerixafor has restricted its use in Mexico, where one vial of 24 mg is priced at $7,500 USD.…”